# A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

> **NCT02337738** · PHASE2,PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 404 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** TVP-1012 1mg
- **DRUG:** TVP-1012 0.5mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02337738
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-27
- **Primary completion:** 2016-09-17
- **Final completion:** 2016-09-17
- **Target enrollment:** 404 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337738, "A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02337738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*